Anticoagulant Pharmacology Quiz

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is a critical factor that may require monitoring LMWHs?

Pulmonary disease

Renal dysfunction (correct)

High blood pressure

Chronic pain

What is the first step to take if a patient experiences hemorrhagic stroke due to Heparin?

Increase the Heparin dosage

Start anticoagulant therapy

Administer Vitamin K

Discontinue Heparin and administer Protamine sulfate (correct)

Which of the following is NOT a hypersensitivity reaction to Heparin?

Increased platelet count (correct)

Urticaria

Chills

Anaphylaxis

What serious condition can occur as a result of Heparin administration?

Heparin-induced thrombocytopenia (HIT) Signup and view all the answers

What adverse effect can result from prolonged use of Heparin?

Osteoporosis Signup and view all the answers

What is the primary mechanism of action of Warfarin?

Inhibition of clotting factor synthesis by reducing Vitamin K Signup and view all the answers

Which of the following best describes the pharmacokinetics of Warfarin?

Extensively binds to plasma albumin, around 97% Signup and view all the answers

What is a significant consequence of the drug interaction between Warfarin and Aspirin?

Aspirin displaces Warfarin from plasma proteins, increasing its free fraction Signup and view all the answers

Which of the following therapeutic uses is associated with Warfarin?

Prophylaxis of venous thromboembolism Signup and view all the answers

What is the latency period before the anticoagulant effects of Warfarin are observed?

36-48 hours Signup and view all the answers

What is the mechanism of action of Dipyridamole?

Elevates cytoplasmic cAMP in vascular tissue and platelets. Signup and view all the answers

Which drug is NOT considered a GP IIb/IIIa receptor blocker?

Dipyridamole Signup and view all the answers

What is the primary use of Abciximab?

Management of unstable angina prior to PCI. Signup and view all the answers

What adverse effect is particularly concerning when using GP IIb/IIIa receptor blockers with anticoagulants?

Bleeding Signup and view all the answers

Which endogenous inhibitor helps to restrict coagulation at the site of vascular injury?

Protein C Signup and view all the answers

What mechanism does Heparin primarily use as an anticoagulant?

Inhibits the action of coagulation factors. Signup and view all the answers

Which pathway does not involve tissue factor during blood coagulation?

Intrinsic pathway Signup and view all the answers

In the coagulation cascade, which factor is activated by tissue factor?

Factor VII Signup and view all the answers

What is a primary indication for Vorapaxar?

Recent myocardial infarction Signup and view all the answers

What is the primary action of thrombolytic drugs?

Facilitate the conversion of Plasminogen to Plasmin Signup and view all the answers

Which of the following side effects is associated with Warfarin?

Teratogenic effects Signup and view all the answers

What is the initial management for minor bleeding caused by Warfarin?

Drug withdrawal or administration of Vit K Signup and view all the answers

How is Vorapaxar primarily eliminated from the body?

In feces Signup and view all the answers

What is a significant risk associated with Vorapaxar use?

Life-threatening bleeding Signup and view all the answers

What is the half-life (t1/2) of Vorapaxar?

20 hours Signup and view all the answers

What is the primary mechanism of action for thrombolytic drugs?

Dissolve clots by converting Plasminogen to Plasmin Signup and view all the answers

What is the molecular weight range of Heparin?

15,000-20,000 Signup and view all the answers

What is a primary therapeutic use of Low-Molecular Weight Heparins?

Prophylaxis of post-operative thrombosis Signup and view all the answers

Which statement about the administration of Heparin is correct?

It is administered by SC or IV bolus followed by slow IV infusion. Signup and view all the answers

What is the mechanism of action for Heparin?

Forms a complex with ATIII to inactivate Thrombin and factor Xa. Signup and view all the answers

How does the half-life of Heparin compare to Low-Molecular Weight Heparins?

Heparin has a shorter half-life than LMWH. Signup and view all the answers

What tests are used to monitor the anticoagulant activity of Heparin?

Activated partial thromboplastin time (aPTT) Signup and view all the answers

Which of the following is true about the safety of Heparin during pregnancy?

It is safe and does not cross the placenta. Signup and view all the answers

Which option correctly describes the administration frequency of Low-Molecular Weight Heparins compared to Heparin?

LMWHs are given less frequently, once or twice daily, compared to Heparin. Signup and view all the answers

Which condition is NOT indicated for the use of thrombolytic drugs?

Hemorrhagic stroke Signup and view all the answers

What is a major contraindication for the use of thrombolytic drugs?

Pregnancy Signup and view all the answers

Which of the following is a common cause of vitamin K deficiency?

Inadequate dietary intake Signup and view all the answers

What is the recommended treatment for vitamin K deficiency in newborns?

Injection of Phytonadione Signup and view all the answers

Which class of drugs works by inhibiting fibrinolysis?

Antiplasmin agents Signup and view all the answers

Desmopressin is primarily used for which of the following conditions?

Diabetes insipidus Signup and view all the answers

What is one of the risks associated with the use of antiplasmin agents?

Renal damage Signup and view all the answers

What condition would NOT cause inadequate blood clotting?

Overhydration Signup and view all the answers

Study Notes

Anticoagulants and Antiplatelet Agents

Thrombosis is the formation of unwanted clots within blood vessels.
Thrombotic disorders include myocardial infarction (MI), deep venous thrombosis (DVT), pulmonary embolism (PE), and acute ischemic stroke.
Thrombus: a clot that adheres to a vessel wall.
Embolus: a thrombus that detaches from a vessel wall and floats in the blood.
Both thrombus and embolus are dangerous and can occlude blood vessels.
Arterial thrombosis typically forms at atherosclerotic plaques in medium-sized vessels. It consists of a platelet-rich clot.
Venous thrombi are rich in fibrin with fewer platelets and are often triggered by blood stasis or inappropriate activation of the coagulation cascade.
Intact endothelial cells secrete inhibitors of platelet aggregation, such as prostacyclin (Prostaglandin I2) and nitric oxide (NO).
Damaged endothelium secrets less of these inhibitors, leading to platelet aggregation.
Platelet activation occurs when the vessel wall is injured, exposing subendothelial matrix proteins like collagen and von Willebrand factor.
Platelet activation results in platelet adherence and activation, and secretion/synthesis of vasoconstrictors and platelet-recruiting/activating molecules.
Products secreted from platelet granules include adenosine diphosphate (ADP) which is a powerful inducer of platelet aggregation; serotonin (5-HT) stimulates aggregation and vasoconstriction; thromboxane A2 (TXA2), synthesized from arachidonic acid, acts as a platelet activator and a potent vasoconstrictor.
Platelet aggregation is the process where activated platelets stick together using GPIIb/IIIa receptors and fibrinogen. Coagulation system cascade is activated concurrently leading to thrombin generation and a fibrin clot.
COX-1 inhibition is a method to prevent platelet aggregation.
Aspirin irreversibly inhibits the COX-1 enzyme in platelets, preventing TXA2 synthesis and thus, aggregation.
Platelets lack nuclei, hence cannot produce new COX-1.
Inhibition of platelet aggregation by aspirin lasts for the life of the platelet (7-10 days).
The recommended daily dose of aspirin is 50-325 mg.
Aspirin is used for preventative treatments like transient cerebral ischemia and myocardial infarction (MI) prevention.
Aspirin is passively absorbed and quickly metabolized into salicylic acid.
Salicylic acid is further metabolized by the liver or excreted renally unchanged.
Aspirin half-life is 15-20 minutes; salicylic acid half-life is 3-12 hours.
A side effect of aspirin is increased bleeding time.
Other COX-1 inhibitors like Ibuprofen are reversible inhibitors and compete with Aspirin for the enzyme binding site.
They prevent the irreversible inhibition of COX-1.

Blockade of ADP Receptors

Ticlopidine, Clopidogrel, Prasugrel, and Ticagrelor block P2Y12 ADP receptors.
All are irreversible except Ticagrelor.
Ticagrelor and Prasugrel need 1-4 hours for maximum efficacy, while Ticlopidine and Clopidogrel require 3-5 days.
Clopidogrel is a prodrug, its therapeutic efficacy solely depends on its active metabolite (generated by CYP2C19).
It's susceptible to genetic polymorphism.
Poor metabolizers of clopidogrel may need another antiplatelet drug.
Clopidogrel is used for prevention of thrombosis with recent MI or stroke, acute coronary syndrome, and percutaneous coronary intervention (PCI).
Ticlopidine is used when other therapies are not tolerated due to life-threatening hematologic reactions.

Blockade of GP IIb/IIIa Receptors

Abciximab, Eptifibatide, and Tirofiban block GP IIb/IIIa receptors.
They prevent the binding of fibrinogen and von Willebrand factor.
Abciximab is a monoclonal antibody; Eptifibatide is a cyclic peptide; Tirofiban is a chemical compound.
These are often given intravenously with heparin and aspirin to prevent cardiac ischemia post-PCI.

Phosphodiesterase III (PDE III) Inhibitors

Dipyridamole elevates cytoplasmic cAMP in vascular tissue and platelets.
It decreases TXA2 synthesis, causing vasodilation and reduced platelet aggregation.
Dipyridamole is commonly used in stroke prevention and usually given with aspirin.

Blood Coagulation

The intrinsic pathway of blood coagulation begins with vascular injury and exposes collagen to blood.
The extrinsic pathway begins with vascular injury and exposes tissue factor (thromboplastin).
Both pathways ultimately lead to thrombin formation, converting fibrinogen into fibrin.
Endogenous inhibitors, such as protein C, protein S, tissue factor pathway inhibitor, and antithrombin III (ATIII), naturally restrict clotting to the site of injury.

Anticoagulants

Anticoagulants work by either inhibiting the action of coagulation factors (e.g., heparin) or inhibiting the synthesis of these factors (e.g., warfarin).
Heparin is a large sulfated polysaccharide polymer.
It has a molecular weight of 15,000-20,000 and is highly acidic.
It can be neutralized by protamine, a basic molecule, which acts as an antidote.
Heparin has a half-life of 1.5 hours and is administered as a subcutaneous (SC) or intravenous (IV) bolus (loading dose), followed by slow IV infusion; causing hematomas if given intramuscularly (IM).
Low-molecular-weight heparins (LMWHs) have a greater bioavailability and a longer duration of action (3-12 hours).
LMWHs are administered subcutaneously (SC) once or twice daily and do not require monitoring as frequently as heparin.
Heparin and LMWHs prevent the conversion of fibrinogen to fibrin by irreversibly inactivating thrombin and factor Xa.

Fondaparinux

Fondaparinux is a small synthetic drug similar to LMWHs.
It selectively binds to antithrombin III and increases its neutralization of factor Xa.
It is used for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
Fondaparinux has a half life of 17-21 hours and is eliminated renally.
Serious renal impairment is a contraindication for fondaparinux.
Bleeding is a side effect of fondaparinux.

Direct Thrombin (IIa) Inhibitors

Direct thrombin inhibitors include argatroban, bivalirudin, desirudin, and dabigatran etexilate.
Dabigatran etexilate can be administered orally.
These inhibit thrombin (IIa) directly, thus preventing fibrin formation.
All are eliminated renally except argatroban (hepatic metabolism).
The drugs are used as alternatives to heparin in patients with a history of heparin-induced thrombocytopenia (HIT). They can also be used during PCI, unstable angina angioplasty, and preventing DVT post hip replacement surgery.
Dabigatran etexilate is used for preventing stroke and embolism in patients with atrial fibrillation.
Bleeding is a side effect, but an antidote is available for Dabigatran, idarucizumab.
aPTT monitoring is needed for these drugs, except dabigatran etexilate.

Inhibitors of Factor Xa

Rivaroxaban and apixaban are inhibitors of factor Xa.
They directly inhibit factor Xa and thus thrombin generation.
Rivaroxaban and apixaban are administered orally and eliminated renally.
They prevent DVT, PE, and stroke. A bleeding side effect is possible, with coagulation factor Xa recombinant being an antidote.

Coumarin Anticoagulants (Warfarin)

Warfarin is a coumarin anticoagulant.
It's used as a rodenticide, but also in clinical settings.
The therapeutic window of warfarin is narrow.
Continuous monitoring by INR test is needed to carefully adjust warfarin dosage (target range: 2-3, 2.5-3.5 for some patients like those with prosthetic valves).
Warfarin works by reducing vitamin K which inhibits clotting factors II, VII, IX, and X.
Warfarin is used in prophylaxis/treatment for DVT and PE, and thromboembolic disorders like atrial fibrillation or in prosthetic valve patients to prevent thromboembolism.

Mechanism of Action of Warfarin

Warfarin blocks the regeneration of vitamin K.
This leads to a reduced amount of functional clotting factors II, VII, IX, and X.

Major Drug Interactions of Warfarin

CYP450 inhibitors (e.g., Amiodarone, SSRIs) increase the anticoagulant effect of warfarin.
CYP450 inducers (e.g., Phenytoin, Carbamazepine, barbiturates) decrease the anticoagulant effect of warfarin.
Aspirin displaces warfarin from plasma proteins, increasing the free warfarin fraction and anticoagulant activity. It also inhibits platelet function.
Antibiotics eradicate intestinal normal flora bacteria which decreases vitamin K production potentially increasing warfarin's anticoagulant activity.

Side Effects of Warfarin

Bleeding is a primary side effect which requires monitoring by INR or PT test.
Warfarin is teratogenic.

Management of Warfarin Toxicity

For minor bleeding, discontinue warfarin and administer vitamin K.
For serious bleeding, high doses of parenteral vitamin K, whole blood, or frozen plasma/concentrates of blood factors are needed.

New Antiplatelet Medications (Vorapaxar)

Vorapaxar is the first in a new drug class—a protease-activated receptor-1 (PAR-1) antagonist.
It blocks thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen.
Vorapaxar is used for recent MI or established peripheral artery disease.

Thrombolytic Drugs

Thrombolytics include streptokinase, alteplase, reteplase, tenecteplase, and urokinase.
They convert plasminogen to plasmin, which hydrolyzes fibrin meshwork and dissolves clots causing tissue reperfusion.
Thrombolytics are normally administered with antiplatelet or anticoagulant drugs.
They are typically given intravenously (IV).
Thrombolytics are effective in acute MI, acute ischemic stroke(if no prior history of hemorrhagic stroke), and acute DVT or PE.

Contraindications of Different Drugs

Contraindications for different drugs (anticoagulants, thrombolytics) include:
- Bleeding disorders (e.g., hemophilia)
- Alcoholism
- Recent surgeries (e.g., brain, eye, spinal cord)
- History of heparin-induced thrombocytopenia (HIT)
- Pregnancy
- Healing wounds
- Intracranial bleeding
- Brain tumor
- Head trauma
- Metastatic cancer

Drugs Used to Treat Bleeding

The causes of inadequate blood clotting include vitamin K deficiency, genetic mutations of clotting factors (e.g., hemophilia A or B), drug-induced issues (e.g., thrombocytopenia), etc
Vitamin K Deficiency's causes are often : Elderly with impaired fat absorption, Newborns, Dietary deficiency, and Antimicrobial therapy.
Vit K deficiency treatment involves administering oral or parenteral Phytonadione (vit K).

Clotting Factors & Desmopressin

Clotting factors can be obtained through recombinant DNA technology.
Desmopressin (vasopressin V2 receptor agonist) can increase plasma concentrations of von Willebrand factor (vWF) and factor VIII thereby being used in patients with vWF disorders or mild hemophilia A.

Antiplasmin Agents

Aminocaproic acid, tranexamic acid, and aprotinin are anti-plasmin agents.
Their mechanism of action is to inhibit plasminogen activation to prevent fibrinolysis.
They are used to prevent or manage acute bleeding episodes in patients with hemophilia or other bleeding disorders.
Such treatments have risks of MI, stroke, and renal damage.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

Test your knowledge on the pharmacology of anticoagulants, particularly Heparin and Warfarin. This quiz covers critical factors in monitoring, adverse effects, drug interactions, and pharmacokinetics. Perfect for students studying pharmacology or nursing.